Home » Newsletters » BioWorld

BioWorld

Aug. 31, 1994

View Archived Issues

CORRECTIONS

ALTEON GETS FDA PERMISSION TO BROADEN PHASE III KIDNEY DISEASE TRIAL

OTHER NEWS TO NOTE

APPOINTMENTS AND ADVANCEMENTS

ONCOLOGIX GETS RIGHTS TO DEVELOP MERCK DRUG FOR POTENTIAL CANCER

ICAGEN EXPANDS DISCOVERYAGREEMENT WITH LILLY

SERENDIPITOUS NEW INDICATION DISCOVERED FOR INTERFERON

ROCHE, SYNTEX MERGER CLEARS FINAL FTC HURDLE

VASCULAR THERAPEUTICS SECURES $4M IN FIRST FINANCING ROUND

INDIAN SCIENTISTS HONE VACCINE FOR CONTROL OF HUMAN FERTILITY

GOVERNMENT LABS LEAD IN BIOTECH INVENTIONS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...